Current recommendations comprise echocardiographic evaluation of CHD every three to six months, depending on clinical presentation and laboratory measurements, including N-terminal-pro hormone B-type natriuretic peptide (NTproBNP) and 5-HIAA [1]. Here, NPPB is linked to coronary artery disorder.